William Wyman appointed Amorfix Chairman of the Board

TSX: AMF

TORONTO, June 12, 2014 /CNW/ - Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that Mr. William Wyman has been appointed Chairman of the Board.  Dr. Neil Cashman, interim Chairman, will remain as Chief Scientific Officer and member of the Board of Directors.   

"We are extremely pleased and fortunate to have Mr. Wyman assume the responsibility as Chairman of the Board", said Dr. Robert Gundel, Amorfix President and CEO.  "Bill brings many years of business experience leading and developing world-class companies and his leadership will be instrumental in bringing Amorfix to the next level.  On behalf of the entire Board of Directors, I would like to thank Dr. Cashman for his leadership and many hours of hard work and dedication as interim Chairman." 

Mr. Wyman began his career at the management consulting firm Booz Allen and Hamilton and eventually became President of the Management Consulting Group, a member of the executive committee, and a member of the Board of Directors.  Mr. Wyman co-founded the management consulting firm, Oliver Wyman & Co. which eventually merged with the consulting group at Marsh & McLennan under the Oliver Wyman name.  Mr. Wyman was a board member at Donaldson, Lufkin and Jenrette and has served as a director/advisor to more than a dozen public and private companies.  He also has served as an advisor to several private equity partnerships.

Mr. Wyman is a member of the Board of Dartmouth Hitchcock Medical Center, and Chairman of the Norris Cotton Cancer Center Directors Advisory Council.  Mr. Wyman received his BA from Colgate University, and his MBA from the Harvard Business School.

About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development company developing therapeutic antibodies and diagnostics targeting misfolded protein diseases. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this technology, Amorfix is developing novel antibody therapeutics and companion diagnostics for cancer and amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample: Epitope Protection™ and AMFIA™, an ultra-sensitive dual-bead immunoassay. Use of these technologies has generated a cerebrospinal fluid (CSF) screening test for both Alzheimer's disease (AD) and mild cognitive impairment (MCI), and an ultrasensitive method for detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF and blood from animal models of AD. For more information about Amorfix, visit www.amorfix.com.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Amorfix Life Sciences Ltd.

For further information: Dr. Robert Gundel, President and Chief Executive Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6957, Fax: (416) 847-6899, bob.gundel@amorfix.com; Warren Whitehead, Chief Financial Officer, Amorfix Life Sciences Ltd., Tel: (416) 644-7358, Fax: (416) 847-6899, warren.whitehead@amorfix.com